David A. Amato

5.3k total citations · 1 hit paper
51 papers, 3.3k citations indexed

About

David A. Amato is a scholar working on Experimental and Cognitive Psychology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, David A. Amato has authored 51 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Experimental and Cognitive Psychology, 10 papers in Immunology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in David A. Amato's work include Sleep and related disorders (12 papers), Psoriasis: Treatment and Pathogenesis (8 papers) and Sleep and Wakefulness Research (8 papers). David A. Amato is often cited by papers focused on Sleep and related disorders (12 papers), Psoriasis: Treatment and Pathogenesis (8 papers) and Sleep and Wakefulness Research (8 papers). David A. Amato collaborates with scholars based in United States, Canada and United Kingdom. David A. Amato's co-authors include Judy Caron, Thomas Roth, Thomas Wessel, Andrew D. Krystal, Robert Rubens, James K. Walsh, Masanori Shiraki, W. Vaughn McCall, Ernest C. Borden and Eugene Laska and has published in prestigious journals such as Nature, New England Journal of Medicine and Journal of Clinical Oncology.

In The Last Decade

David A. Amato

50 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

2016 650 citations Kenneth B. Gordon, Andrew Blauvelt et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David A. Amato United States	26	1.0k	945	861	514	488	51	3.3k
Gene V. Wallenstein United States	33	422 0.4×	1.8k 1.9×	1.3k 1.5×	143 0.3×	1.2k 2.4×	81	7.7k
Ellen Snyder United States	24	1.2k 1.2×	1.2k 1.3×	288 0.3×	815 1.6×	485 1.0×	50	2.9k
James Signorovitch United States	36	48 0.0×	110 0.1×	551 0.6×	344 0.7×	880 1.8×	278	5.5k
Junying Zhou China	29	781 0.8×	837 0.9×	168 0.2×	361 0.7×	228 0.5×	104	3.3k
Scott E. Smith United States	31	193 0.2×	127 0.1×	498 0.6×	38 0.1×	2.1k 4.2×	113	4.6k
Kate Fisher United States	22	94 0.1×	210 0.2×	209 0.2×	180 0.4×	662 1.4×	44	2.3k
Kenneth Abrams United States	27	461 0.5×	102 0.1×	425 0.5×	21 0.0×	900 1.8×	80	3.3k
Shona Lang United Kingdom	26	72 0.1×	254 0.3×	261 0.3×	86 0.2×	1.2k 2.5×	56	3.8k
Denái R. Milton United States	30	91 0.1×	474 0.5×	310 0.4×	19 0.0×	740 1.5×	138	3.4k
Prashni Paliwal United States	26	361 0.4×	416 0.4×	258 0.3×	46 0.1×	776 1.6×	38	3.3k

Countries citing papers authored by David A. Amato

Since Specialization

Citations

This map shows the geographic impact of David A. Amato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Amato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Amato more than expected).

Fields of papers citing papers by David A. Amato

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Amato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Amato. The network helps show where David A. Amato may publish in the future.

Co-authorship network of co-authors of David A. Amato

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Amato. A scholar is included among the top collaborators of David A. Amato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Amato. David A. Amato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Warren, Richard B., Melinda Gooderham, Russel Burge, et al.. (2019). Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. Journal of the American Academy of Dermatology. 82(5). 1138–1149. 44 indexed citations

Armstrong, April W., David A. Amato, William J. Huster, Clement K. Ojeh, & Abby S. Van Voorhees. (2019). Achievement of the National Psoriasis Foundation treatment targets with ixekizumab: Pooled analyses from 4 clinical studies. Journal of the American Academy of Dermatology. 85(2). 330–336. 1 indexed citations

Gordon, Kenneth B., Andrew Blauvelt, Kim Papp, et al.. (2016). Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. New England Journal of Medicine. 375(4). 345–356. 650 indexed citations breakdown →

Barbier, Ann, et al.. (2013). The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5years and older treated with intravenous idursulfase. Molecular Genetics and Metabolism. 110(3). 303–310. 43 indexed citations

Schiffmann, Raphael, Markus Ries, Derek Blankenship, et al.. (2013). Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa. Genetics in Medicine. 15(12). 983–989. 24 indexed citations

Kalb, Robert E., Andrew Blauvelt, Howard Sofen, et al.. (2013). Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.. PubMed. 12(8). 874–80. 20 indexed citations

Roth, Thomas, J. M. Price, David A. Amato, et al.. (2009). The Effect of Eszopiclone in Patients With Insomnia and Coexisting Rheumatoid Arthritis. The Primary Care Companion to The Journal of Clinical Psychiatry. 11(6). 292–301. 33 indexed citations

Rosenberg, Russell, James Roach, Martin B. Scharf, & David A. Amato. (2007). A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome. Sleep Medicine. 8(5). 464–470. 71 indexed citations

Walsh, James K., Andrew D. Krystal, David A. Amato, et al.. (2007). Nightly Treatment of Primary Insomnia With Eszopiclone for Six Months: Effect on Sleep, Quality of Life, and Work Limitations. SLEEP. 30(8). 959–968. 167 indexed citations

10.

Fava, Maurizio, W. Vaughn McCall, Andrew D. Krystal, et al.. (2006). Eszopiclone Co-Administered With Fluoxetine in Patients With Insomnia Coexisting With Major Depressive Disorder. Biological Psychiatry. 59(11). 1052–1060. 320 indexed citations

11.

Scharf, Martin B., Milton K. Erman, Russell Rosenberg, et al.. (2005). A 2-Week Efficacy and Safety Study of Eszopiclone in Elderly Patients with Primary Insomnia. SLEEP. 28(6). 720–727. 86 indexed citations

12.

Rosenberg, Russell, Judy Caron, Thomas Roth, & David A. Amato. (2004). An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults. Sleep Medicine. 6(1). 15–22. 43 indexed citations

13.

Zammit, Gary, et al.. (2004). Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Current Medical Research and Opinion. 20(12). 1979–1991. 105 indexed citations

14.

Krystal, Andrew D., James K. Walsh, Eugene Laska, et al.. (2004). The Sustained 6-Month Efficacy of Eszopiclone in the Treatment of Chronic Insomnia. SLEEP. 27(2). 346–347. 3 indexed citations

15.

Krystal, Andrew D., James K. Walsh, Eugene Laska, et al.. (2003). Sustained Efficacy of Eszopiclone Over 6 Months of Nightly Treatment: Results of a Randomized, Double-Blind, Placebo-Controlled Study in Adults with Chronic Insomnia. SLEEP. 26(7). 793–799. 312 indexed citations

16.

Pasche, Boris, Milton K. Erman, Roza Hayduk, et al.. (1996). Effects of Low Energy Emission Therapy in Chronic Psychophysiological Insomnia. SLEEP. 19(4). 327–336. 23 indexed citations

17.

Boivin, Michael J., Bruno Giordani, Stanley Berent, et al.. (1992). Verbal Fluency and Positron Emission Tomographic Mapping of Regional Cerebral Glucose Metabolism. Cortex. 28(2). 231–239. 71 indexed citations

18.

Borden, Ernest C., David A. Amato, John H. Edmonson, Paul S. Ritch, & Masanori Shiraki. (1990). Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer. 66(5). 862–867. 65 indexed citations

19.

Shiraki, Masanori, Horatio T. Enterline, John J. Brooks, et al.. (1989). Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The eastern cooperative oncology group (ECOG) experience. Cancer. 64(2). 484–490. 50 indexed citations

20.

Amato, David A., et al.. (1988). The Prodrome of Bullous Pemphigoid. International Journal of Dermatology. 27(8). 560–563. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact